Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Times Interest Earned (2019 - 2023)

UroGen Pharma's Times Interest Earned history spans 5 years, with the latest figure at -$0.1 for Q4 2023.

  • For Q4 2023, Times Interest Earned fell 138.89% year-over-year to -$0.1; the TTM value through Dec 2023 reached -$0.46, down 138.1%, while the annual FY2023 figure was -$0.46, 138.1% down from the prior year.
  • Times Interest Earned reached -$0.1 in Q4 2023 per URGN's latest filing, down from $0.26 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of $0.26 in Q4 2022 to a low of -$0.79 in Q4 2019.
  • Average Times Interest Earned over 5 years is -$0.24, with a median of -$0.2 recorded in 2021.
  • Peak YoY movement for Times Interest Earned: skyrocketed 232.2% in 2022, then plummeted 138.89% in 2023.
  • A 5-year view of Times Interest Earned shows it stood at -$0.79 in 2019, then soared by 55.03% to -$0.35 in 2020, then soared by 44.11% to -$0.2 in 2021, then skyrocketed by 232.2% to $0.26 in 2022, then tumbled by 138.89% to -$0.1 in 2023.
  • Per Business Quant, the three most recent readings for URGN's Times Interest Earned are -$0.1 (Q4 2023), $0.26 (Q4 2022), and -$0.2 (Q4 2021).